Bristol-Myers Squibb Company ((BMY)), Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer and Bristol-Myers Squibb are conducting a Phase 1b clinical study titled A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30). The study aims to evaluate the safety and tolerability of combining elranatamab, a BCMA-CD3 bispecific antibody, with iberdomide, a cereblon-modulating agent, in treating patients with relapsed or refractory multiple myeloma, a cancer affecting plasma cells.
The study involves two parts: Part 1 focuses on dose escalation to assess safety and tolerability, while Part 2 involves dose randomization to determine the optimal dose. Participants receive elranatamab via subcutaneous injection and iberdomide orally over 28-day cycles until disease progression, unacceptable side effects, or withdrawal from the study.
This interventional study is randomized, with a sequential intervention model and no masking, primarily aiming at treatment. The study began on February 20, 2024, with an estimated completion date not yet specified, and the latest update was submitted on July 2, 2025.
For investors, the study’s progress could influence Pfizer and Bristol-Myers Squibb’s stock performance, as successful outcomes may enhance their competitive position in the oncology market. The study’s results could impact investor sentiment and market dynamics, given the high stakes in developing effective multiple myeloma treatments.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.